GO:0060338 regulation of type I interferon-mediated signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0060338 describes any process that modulates the rate, frequency or extent of type I interferon-mediated signaling, a central antiviral and immunoregulatory cascade.
• Type I interferons (IFN-alpha/beta) bind IFNAR1/IFNAR2, activating JAK1/TYK2 and STAT1/STAT2/IRF9 to induce hundreds of interferon-stimulated genes.
• Regulation occurs at multiple nodes including nucleic acid sensing, TBK1/IKKepsilon activation, ubiquitination, and negative feedback by SOCS and phosphatases.
• Dysregulation of this pathway contributes to viral susceptibility, autoimmunity, and tumor immune evasion, making it a major therapeutic target.
• Metabolic and transcriptional regulators such as EGR2 and HERC2 fine-tune type I IFN signaling in neutrophils, T cells, and hepatocytes.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of regulators within this pathway.
Description
The Gene Ontology term GO:0060338, regulation of type I interferon-mediated signaling pathway, refers to any process that modulates the rate, frequency or extent of signaling initiated by type I interferons such as IFN-alpha and IFN-beta. Type I interferon signaling is a cornerstone of innate antiviral immunity and also shapes adaptive immune responses, tumor surveillance, and inflammatory homeostasis. Because the pathway must be tightly controlled to avoid immunopathology, a diverse set of positive and negative regulators act at the receptor, kinase, adaptor, and transcriptional levels. Understanding these regulatory mechanisms is essential for virology, cancer immunology, and autoimmunity research. This article integrates the QuickGO definition with verified PubMed literature to summarize the mechanisms, key genes, disease links, and experimental strategies relevant to GO:0060338.
regulation of type I interferon-mediated signaling pathway At A Glance
| GO ID | GO:0060338 |
|---|---|
| GO term | regulation of type I interferon-mediated signaling pathway |
| Ontology | biological_process |
| Synonym | regulation of type I interferon-mediated signalling pathway |
| Definition | Any process that modulates the rate, frequency or extent of a type I interferon-mediated signaling pathway. |
| Major function | Controls the intensity, duration, and specificity of cellular responses to IFN-alpha/beta, thereby shaping antiviral, antitumor, and immunoregulatory outputs. |
| Upstream inputs | Nucleic acid sensors, cytokine receptor engagement, and metabolic or stress signals that converge on TBK1/IKKepsilon and JAK-STAT components. |
| Key effectors | STAT1, STAT2, IRF9, IRF3, IRF7, and interferon-stimulated genes. |
| Disease relevance | Viral infection, cancer immunity, autoinflammation, and T cell dysfunction. |
What Is GO:0060338?
GO:0060338 is a biological process term defined as any process that modulates the rate, frequency or extent of a type I interferon-mediated signaling pathway. In practical terms, it encompasses all molecular events that enhance, dampen, or temporally shape cellular responses to IFN-alpha and IFN-beta, including regulation of receptor activation, JAK-STAT transduction, interferon-stimulated gene (ISG) transcription, and negative feedback loops.
Why Is regulation of type I interferon-mediated signaling pathway Important in Cell Biology?
Regulation of type I interferon-mediated signaling is critically important because it determines whether the host mounts a protective antiviral or antitumor response or instead suffers from excessive inflammation or immune evasion. The pathway is also a central node in immunotherapy, where modulating its activity can enhance CAR T cell function or improve responses to immune checkpoint blockade. Consequently, identifying regulators within GO:0060338 is a high-priority goal for both basic immunology and translational medicine.
• Controls antiviral defense against diverse RNA and DNA viruses through interferon-stimulated genes.
• Shapes tumor immunity and influences responsiveness to cancer immunotherapy.
• Regulates neutrophil antiviral capabilities and inflammatory output.
• Modulates CAR T cell intrinsic dysfunction and persistence.
• Involved in hepatocyte anti-HBV immune responses via HERC2-TBK1 regulation.
• Provides targets for synthetic TBK1 activators to boost antiviral and antitumor immunity.
• Links metabolic states to innate antiviral immunity.
• Dysregulation can contribute to autoimmunity and chronic inflammation.
• Serves as a paradigm for understanding cytokine signaling feedback control.
• Enables CRISPR-based functional genomics of host-pathogen interactions.
What Happens During regulation of type I interferon-mediated signaling pathway?
Interferon production and receptor engagement
In simple terms: Cells sense viral nucleic acids and release interferon, which then binds to receptors on the same or neighboring cells.
Type I interferon-mediated signaling begins when nucleic acid sensors detect viral RNA or DNA and trigger interferon production. Secreted IFN-alpha/beta bind the IFNAR1/IFNAR2 receptor complex, which activates associated JAK1 and TYK2 kinases. Regulation at this stage includes control of interferon synthesis, receptor availability, and ligand competition, all of which set the threshold for downstream signaling.
JAK-STAT transduction and ISG transcription
In simple terms: The receptor activates kinases that phosphorylate STAT proteins, which move to the nucleus and turn on antiviral genes.
Activated JAK1 and TYK2 phosphorylate STAT1 and STAT2, which assemble with IRF9 into the ISGF3 complex. ISGF3 translocates to the nucleus and binds interferon-stimulated response elements to induce hundreds of interferon-stimulated genes. Regulation of this step includes phosphatase-mediated dephosphorylation, SOCS protein feedback, and nuclear trafficking controls that determine the amplitude and duration of the transcriptional response.
TBK1/IKKepsilon and IRF activation
In simple terms: Other kinases amplify the response by activating IRF transcription factors that produce more interferon.
Nucleic acid sensing pathways converge on TBK1 and IKKepsilon, which phosphorylate IRF3 and IRF7 to drive interferon gene transcription. This positive feedback loop is tightly regulated by ubiquitination and adaptor protein availability. For example, HERC2 promotes K33-linked ubiquitination of TBK1 to enhance type I interferon-mediated anti-HBV immune responses in hepatocytes.
Negative feedback and resolution
In simple terms: The cell uses brakes such as SOCS proteins and phosphatases to stop the response once the threat is controlled.
To prevent excessive inflammation, multiple negative regulators terminate type I interferon signaling. These include SOCS1 and SOCS3, which inhibit JAK activity, and phosphatases such as SHP1/SHP2 that dephosphorylate signaling intermediates. Dysregulation of these brakes can lead to chronic interferonopathies or impaired viral clearance.
Metabolic and transcriptional fine-tuning
In simple terms: Cellular metabolism and transcription factors adjust how strongly the interferon response fires.
Metabolic pathways influence interferon-mediated innate antiviral immunity by supplying substrates and energy for signaling and effector functions. Transcriptional regulators such as EGR2 potentiate type I interferon signaling and contribute to CAR T cell-intrinsic dysfunction. These layers of regulation integrate environmental and cell-state cues into the canonical interferon cascade.
Key Genes Involved in GO:0060338 regulation of type I interferon-mediated signaling pathway
The following genes and proteins are central to the regulation of type I interferon-mediated signaling pathway (GO:0060338) based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IFNAR1 | Type I interferon receptor subunit 1 | Receptor-level regulation of IFN-alpha/beta signaling |
| IFNAR2 | Type I interferon receptor subunit 2 | Receptor complex formation and signal initiation |
| JAK1 | Janus kinase 1 | Phosphorylates STAT proteins downstream of IFNAR |
| TYK2 | Tyrosine kinase 2 | Phosphorylates STAT proteins downstream of IFNAR |
| STAT1 | Signal transducer and activator of transcription 1 | Core ISGF3 component driving ISG expression |
| STAT2 | Signal transducer and activator of transcription 2 | Core ISGF3 component driving ISG expression |
| IRF9 | Interferon regulatory factor 9 | DNA-binding subunit of ISGF3 |
| IRF3 | Interferon regulatory factor 3 | TBK1 substrate inducing interferon gene transcription |
| IRF7 | Interferon regulatory factor 7 | Amplifies type I interferon production |
| TBK1 | TANK-binding kinase 1 | Central kinase in nucleic acid sensing to interferon axis |
| IKBKE | IKKepsilon | TBK1-related kinase activating IRFs |
| HERC2 | HECT and RLD domain containing E3 ubiquitin protein ligase 2 | Promotes K33 ubiquitination of TBK1 to enhance anti-HBV immunity |
| SOCS1 | Suppressor of cytokine signaling 1 | Negative feedback inhibitor of JAK-STAT signaling |
| SOCS3 | Suppressor of cytokine signaling 3 | Negative feedback inhibitor of JAK-STAT signaling |
| EGR2 | Early growth response 2 | Transcriptional regulator potentiating type I IFN signaling in CAR T cells |
| PTPN6 | SHP1 phosphatase | Dephosphorylates signaling intermediates to dampen IFN responses |
| PTPN11 | SHP2 phosphatase | Dephosphorylates signaling intermediates to dampen IFN responses |
How Is regulation of type I interferon-mediated signaling pathway Regulated?
Regulation of type I interferon-mediated signaling is itself controlled by layered mechanisms including metabolic inputs, transcriptional feedback, and post-translational modifications. Metabolic regulation of interferon-mediated innate antiviral immunity has emerged as a key determinant of host defense. Transcriptional regulators such as EGR2 can potentiate type I interferon signaling and contribute to T cell dysfunction. Ubiquitination events, exemplified by HERC2-mediated K33 ubiquitination of TBK1, provide positive regulation of the pathway. Conversely, SOCS proteins and phosphatases provide negative feedback to prevent immunopathology.
regulation of type I interferon-mediated signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TBK1 | Antiviral and antitumor immunity | Knockout or point-mutation cell lines to test TBK1 activation |
| HERC2 | Hepatitis B virus immune response | Hepatocyte knockout and knock-in models |
| EGR2 | CAR T cell dysfunction | Overexpression and knockout in T cells |
| IFNAR1 | Viral susceptibility and interferonopathies | Knockout cell lines and patient-derived cells |
| SOCS1 | Autoinflammation and immune dysregulation | Knockout and overexpression models |
Viral infection and antiviral immunity
Type I interferon-mediated signaling is essential for controlling viral infections, and its regulation determines susceptibility or resistance to viruses such as HBV. Neutrophils rely on type I interferon-mediated regulation to exert antiviral capabilities. Nucleic acid sensing pathways that feed into interferon production are critical for innate antiviral responses during viral infection.
Cancer immunity and immunotherapy
Type I interferon-mediated tumor immunity plays a central role in cancer immunosurveillance and response to immunotherapy. Synthetic TBK1 activators can induce type I interferon-mediated antiviral and antitumor immunity, highlighting therapeutic potential. In CAR T cells, type I interferon signaling via EGR2 potentiates T cell-intrinsic dysfunction, suggesting that regulating this pathway could improve cell therapies.
Autoinflammation and immune dysregulation
Excessive or prolonged type I interferon signaling is associated with autoinflammatory and autoimmune conditions, making negative regulators such as SOCS proteins and phosphatases important disease modifiers. Metabolic dysregulation can also perturb interferon-mediated innate antiviral immunity, linking metabolic disease to altered host defense.
From regulation of type I interferon-mediated signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene a positive regulator of type I IFN signaling? | CRISPR knockout followed by IFN stimulation and ISG reporter assay |
| Does a specific phosphorylation site control TBK1 activity? | Point-mutation knock-in of phospho-deficient or phospho-mimetic residues |
| How does a regulator affect antiviral immunity in hepatocytes? | Knock-in or knockout hepatocyte cell lines with HBV infection |
| Does overexpression of a regulator enhance antitumor immunity? | Overexpression cell models and tumor-immune co-culture |
| What is the role of a transcriptional regulator in CAR T cells? | Knockout and overexpression in primary T cells |
| How does metabolic state influence IFN signaling? | Metabolic perturbation combined with knockout of metabolic genes |
How to Study the regulation of type I interferon-mediated signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global ISG expression changes | Assessing pathway output after knockout or overexpression |
| Phospho-Western blot | STAT1/STAT2/TBK1/IRF3 phosphorylation | Identifying regulatory nodes |
| Luciferase reporter assay | Interferon-responsive promoter activity | Kinetic analysis of pathway activation |
| Immunofluorescence | Nuclear translocation of ISGF3 | Visualizing signaling activation |
| Viral plaque assay | Antiviral capacity | Testing regulators in infection models |
| Tumor-immune co-culture | Antitumor immunity | Evaluating therapeutic potential |
| CRISPR library screening | Genome-wide regulators of IFN signaling | Discovery of novel pathway components |
Transcriptional profiling of interferon-stimulated genes
RNA-seq and targeted qPCR panels measure interferon-stimulated gene expression to quantify the output of type I interferon-mediated signaling after genetic perturbation. These methods are widely used to assess positive and negative regulators in knockout or overexpression backgrounds.
Phospho-proteomics and signaling assays
Western blotting and phospho-proteomics detect phosphorylation of STAT1, STAT2, TBK1, and IRF3 to pinpoint where a regulator acts within the pathway. These approaches are essential for distinguishing receptor-level from kinase-level regulation.
Reporter assays and imaging
Interferon-responsive luciferase reporters and fluorescence imaging enable kinetic measurement of pathway activation in live cells. Imaging can also reveal nuclear translocation of ISGF3 components.
Functional antiviral and antitumor assays
Viral plaque assays, HBV infection models, and tumor-immune co-culture systems test whether genetic manipulation of a regulator alters antiviral or antitumor immunity. These functional readouts connect molecular regulation to disease-relevant outcomes.
How CRISPR Can Be Used to Study GO:0060338 regulation of type I interferon-mediated signaling pathway
Knockout
CRISPR knockout of candidate genes followed by interferon stimulation and ISG readouts is a powerful approach to identify positive and negative regulators of GO:0060338. For example, knocking out HERC2 in hepatocytes can reveal its role in TBK1 ubiquitination and anti-HBV immunity.
Point Mutation
Point mutations can dissect specific phosphorylation or ubiquitination sites within signaling components such as TBK1 or STAT1. Phospho-deficient or phospho-mimetic knock-in lines help establish causality for individual residues.
Knock-in
Knock-in of tagged or reporter alleles enables tracking of endogenous proteins and real-time monitoring of pathway activation. This is particularly useful for studying nuclear translocation of ISGF3 components.
Overexpression
Overexpression of candidate regulators can test sufficiency for enhancing or suppressing type I interferon-mediated signaling. For instance, overexpressing EGR2 in T cells potentiates interferon signaling and dysfunction.
How EDITGENE Supports regulation of type I interferon-mediated signaling pathway Research
Researchers studying regulation of type I interferon-mediated signaling pathway-related genes often need to determine whether a candidate gene is causally involved in modulating IFN responses, and at which step of the pathway it acts. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for regulation of type I interferon-mediated signaling pathway research.
Frequently Asked Questions About regulation of type I interferon-mediated signaling pathway
What is GO:0060338?
GO:0060338 is the Gene Ontology term for regulation of type I interferon-mediated signaling pathway, defined as any process that modulates the rate, frequency or extent of signaling triggered by type I interferons such as IFN-alpha and IFN-beta.
What genes are involved in regulation of type I interferon-mediated signaling pathway?
Key genes include IFNAR1, IFNAR2, JAK1, TYK2, STAT1, STAT2, IRF9, IRF3, IRF7, TBK1, IKBKE, HERC2, SOCS1, SOCS3, and EGR2.
How does type I interferon signaling work?
Type I interferons bind IFNAR1/IFNAR2, activating JAK1 and TYK2, which phosphorylate STAT1 and STAT2; these form ISGF3 with IRF9 to induce interferon-stimulated genes.
Why is regulation of type I interferon signaling important in cancer?
Type I interferon-mediated tumor immunity is central to cancer immunosurveillance and immunotherapy responses, and modulating the pathway can enhance antitumor immunity.
What diseases are linked to dysregulated type I interferon signaling?
Dysregulation is linked to viral infections, autoinflammation, autoimmunity, and cancer immune evasion.
How can CRISPR be used to study GO:0060338?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of candidate regulators in interferon signaling assays.
What is the role of TBK1 in type I interferon signaling?
TBK1 is a central kinase that phosphorylates IRF3 and IRF7 downstream of nucleic acid sensors, and its activity is regulated by ubiquitination such as HERC2-mediated K33 ubiquitination.
What negative regulators control type I interferon signaling?
SOCS1, SOCS3, and phosphatases such as SHP1 and SHP2 provide negative feedback to prevent excessive interferon responses.
How does metabolism influence type I interferon-mediated immunity?
Metabolic pathways regulate interferon-mediated innate antiviral immunity by supplying energy and substrates and by influencing signaling intermediates.
What experimental models are used to study regulation of type I interferon signaling?
Common models include knockout and overexpression cell lines, reporter assays, viral infection models, and tumor-immune co-culture systems.
Conclusion
GO:0060338, regulation of type I interferon-mediated signaling pathway, is a critical biological process that governs the intensity and duration of cellular responses to IFN-alpha and IFN-beta. Its dysregulation contributes to viral susceptibility, cancer immune evasion, and autoinflammation, making it a high-value target for therapeutic intervention. CRISPR-based functional genomics, combined with transcriptional and proteomic readouts, offers a robust strategy to dissect the regulators within this pathway and translate findings into clinical applications.
References
- 1. Stegelmeier AA et al.. 2021. Type I Interferon-Mediated Regulation of Antiviral Capabilities of Neutrophils.. Int J Mol Sci 22(9) PMID: 33946935
- 2. Zhong T et al.. 2025. Metabolic regulation of interferon-mediated innate antiviral immunity.. Front Immunol 16:1680688 PMID: 41132680
- 3. Yu R et al.. 2022. Type I interferon-mediated tumor immunity and its role in immunotherapy.. Cell Mol Life Sci 79(3):191 PMID: 35292881
- 4. Uddin S et al.. 2004. Mechanisms of type-I interferon signal transduction.. J Biochem Mol Biol 37(6):635-41 PMID: 15607020
- 5. Jung IY et al.. 2023. Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell-Intrinsic Dysfunction.. Cancer Discov 13(7):1636-1655 PMID: 37011008
- 6. Takaoka A et al.. 2019. Regulation of signaling mediated by nucleic acid sensors for innate interferon-mediated responses during viral infection.. Int Immunol 31(8):477-488 PMID: 30985869
- 7. Jeong K et al.. 2026. Discovery of synthetic TBK1 activator inducing type I interferon-mediated antiviral and antitumor immunity.. Mol Ther PMID: 42642934
- 8. Zheng Z et al.. 2025. Hepatocyte-expressed HERC2 enhances type I interferon-mediated anti-HBV immune response by promoting K33 ubiquitination of TBK1.. J Immunol 214(7):1789-1801 PMID: 40381993
